Artivion Inc (NYSE:AORT)

$ 25.28 0.14 (0.56%) Market Cap: 1.06 Bil Enterprise Value: 1.36 Bil PE Ratio: 0 PB Ratio: 3.58 GF Score: 81/100

Q1 2024 Artivion Inc Earnings Call Transcript
May 06, 2024

$21.07 (+0.67%)

Earnings
Q4 2023 Artivion Inc Earnings Call Transcript
Feb 15, 2024

$18.04 (+2.73%)

Earnings
Q3 2023 Artivion Inc Earnings Call Transcript
Nov 02, 2023

$12.95 (+0.54%)

Earnings
Artivion Inc at Deutsche Bank Leveraged Finance Conference Transcript
Oct 03, 2023
Artivion Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Q2 2023 Artivion Inc Earnings Call Transcript
Aug 03, 2023

$16.79 (-1.70%)

Earnings
Q1 2023 Artivion Inc Earnings Call Transcript
May 04, 2023

$13.35 (-0.96%)

Earnings
Artivion Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Q4 2022 Artivion Inc Earnings Call Transcript
Feb 16, 2023

$13.2 (-1.35%)

Earnings
Q3 2022 Artivion Inc Earnings Call Transcript
Nov 03, 2022

$11.4

Earnings
Artivion Inc Investor Update Call Transcript
Sep 23, 2022
Artivion Inc at Deutsche Bank Leveraged Finance Conference Transcript
Sep 21, 2022
Artivion Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Q2 2022 Artivion Inc Earnings Call Transcript
Aug 04, 2022

$21.76 (+0.88%)

Earnings
Artivion Inc at UBS Global Healthcare Conference Transcript
May 23, 2022
Q1 2022 Artivion Inc Earnings Call Transcript
May 05, 2022

$19.16 (-7.44%)

Earnings
Artivion Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2022
Artivion Inc Investor & Analyst Day Transcript
Mar 23, 2022
Q4 2021 Artivion Inc Earnings Call Transcript
Feb 17, 2022

$17.5 (-1.46%)

Earnings
Q3 2021 CryoLife Inc Earnings Call Transcript
Nov 04, 2021

$21.21 (-0.28%)

Earnings
CryoLife Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021
Q2 2021 CryoLife Inc Earnings Call Transcript
Jul 29, 2021

$27.41 (+2.85%)

Earnings
CryoLife Inc at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Q1 2021 CryoLife Inc Earnings Call Transcript
Apr 29, 2021

$23.49 (-0.55%)

Earnings
CryoLife Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2021
Q4 2020 CryoLife Inc Earnings Call Transcript
Feb 11, 2021

$25.41 (+2.79%)

Earnings
CryoLife Inc - Discussing PROACT Xa Clinical Trial Transcript
Dec 07, 2020
Q3 2020 CryoLife Inc Earnings Call Transcript
Nov 04, 2020

$18.29 (-0.71%)

Earnings
CryoLife Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
CryoLife Inc Acquires Ascyrus Medical - Call Transcript
Sep 02, 2020
Q2 2020 CryoLife Inc Earnings Call Transcript
Jul 30, 2020

$18.9 (-1.05%)

Earnings
CryoLife Inc Annual Shareholders Meeting Transcript
May 20, 2020
Q1 2020 CryoLife Inc Earnings Call Transcript
Apr 30, 2020

$22.33 (-3.33%)

Earnings
Q4 2019 CryoLife Inc Earnings Call Transcript
Feb 13, 2020

$30.3 (+1.17%)

Earnings
Q3 2019 CryoLife Inc Earnings Call Transcript
Oct 30, 2019

$23.81 (-2.06%)

Earnings
CryoLife Inc at Deutsche Bank Leveraged Finance Conference Transcript
Sep 25, 2019
CryoLife Inc Update - Acquires Rights to Nexus - Distribution Agreement with Endospan Transcript
Sep 12, 2019
CryoLife Inc at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
CryoLife Inc at Canaccord Genuity Growth Conference Transcript
Aug 08, 2019
Q2 2019 CryoLife Inc Earnings Call Transcript
Jul 30, 2019

$30.49 (+0.89%)

Earnings
Q1 2019 CryoLife Inc Earnings Call Transcript
Apr 30, 2019

$30.66 (+1.52%)

Earnings
CryoLife Inc at Cowen Health Care Conference Transcript
Mar 11, 2019
Q4 2018 CryoLife Inc Earnings Call Transcript
Feb 14, 2019

$25.85 (-14.52%)

Earnings

Artivion Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 08:05PM GMT

Release Date Price: $21.44 (-3.21%)

Transcript

Cecilia E. Furlong

Morgan Stanley, Research Division - Equity Analyst

Thank you for joining us for the second day of the Morgan Stanley Healthcare Conference. I'm Cecilia Furlong Medtech analyst here at Morgan Stanley. It is my pleasure to have (inaudible) with us today, CEO, Pat Mackin. CFO, Ashley Lee, thank you both for joining us.

James Patrick Mackin

Artivion, Inc. - Chairman, President & CEO

Yes, good to be here. Absolutely.

Cecilia E. Furlong

Morgan Stanley, Research Division - Equity Analyst

And quickly disclosures at morganstanley.com/researchdisclosures.

Questions & Answers

Cecilia E. Furlong

Morgan Stanley, Research Division - Equity Analyst

And with that, I want to start on the macro bit in your guide and a few moving factors as we think about from approvals upcoming, your back half guide, what, if anything, is really incorporated from either PerClot initial sales Baxter or else mitral as you think upon an expanded indication going on the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.